Verana Health Logo

Verana Health Develops Qdata MS, a Real World Data, Composite Neurology Research Module for Multiple Sclerosis

SAN FRANCISCO, Nov 16 2022 /PRNewswire/ — Verana Health®– a digital health company that increases quality in real-world data (RWD) – announced today that it is developing Qdata™ MSA neurology Qdata module that will be used to help advance clinical research and develop therapeutic strategies for the treatment of patients with multiple sclerosis (MS). The company made the announcement ahead of the CNS Summit 2022 (Nov. 17 to 20) in Boca Raton, Fla.

Neurology Qdata consists of quality, curated datasets documenting real-world disease data, treatments and outcomes. Available through Verana Health’s Real Evidence (RWE) service offerings, Qdata MS is derived from the American Academy of Neurology Axon Registry®. The Axon Registry, managed by Verana Health’s VeraQ™ population health data engine, is one of the largest – and growing – real-world clinical data registries for neurology. As the Qdata MS module progresses through development, it is estimated to include de-identified, aggregated RWD from approximately 30,000 patients diagnosed with MS, one of the largest longitudinal multiple sclerosis datasets for research use.

MS affects a person’s brain, spinal cord and optic nerves, which make up the central nervous system (CNS). This unpredictable disease causes a person’s immune system to attack the CNS, disrupting signals to and from the rest of the body. Nearly 1 million people live with MS in the US, according to a 2019 study funded by the National Multiple Sclerosis Society. This is more than twice the number of a national study in 1975. MS is almost three times more common among women than men.

Qdata MS provides quality insights into the patient population by applying artificial intelligence to the unstructured data found in clinical notes to help provide a more complete understanding of disease activity and clinical characteristics such as MS phenotype, Expanded Disability Status Score (EDSS) -score and clinical relapse. Using de-identified electronic health record (EHR) data, detailed diagnostic classification outside of International Classification of Diseases (ICDs), and a fine-grained understanding of disease activity, researchers can gain a better understanding of the MS patient journey.

Compiled, de-identified RWD from patients with MS can help provide insights into how patients with this disease live and respond to treatments.

“Qdata MS gives patients and their doctors the opportunity to contribute and lend their anonymous experiences to research and engage the wider neurology community to learn more about this disease,” said Heather MossMD, PhD, Associate Professor at Stanford University and Verana Health medical advisor. “Qdata MS has the potential to provide a more granular view of the MS patient journey that cannot easily be found within structured EHR fields, medical claims, or pharmacy claims. The ability to give meaning to unstructured, de- identified neurologist notes on tens of thousands of MS patients will provide a valuable new data set to help researchers develop and study treatments for various MS patient cohorts.”

The new composite RWD module will benefit life science research by:

  • Clinical development. As MS treatments improve, Qdata can help MS optimize study design.
  • HEARING and medical matters. Qdata MS can help researchers understand and track the patient journey for treated and untreated MS patients, from diagnosis by phenotype to treatment and disease progression.
  • Commercialization. Qdata MS can help reveal treatment performance across Axon Registry practices, clinical characteristics and more, as well as deliver market insights based on details extracted from unstructured clinical notes.

“Qdata MS will help support MS researchers to access informative RWE and potentially enable practices enrolled in the Axon Registry to participate in or help influence ground-breaking clinical research,” said Sujay Jadhav, CEO of Verana Health. “By making this de-identified data available, the American Academy of Neurology and Verana Health are enabling MS researchers to gain a better understanding of this disease and how it can be treated.”

Verana Health is constantly developing new Qdata modules to help deepen understanding about disease, patient journeys and to help physicians and life science organizations improve the quality of care for patients. Verana Health’s first neurology module, Qdata SMA, launched in April 2022. It provides a real-world, de-identified data set reflective of patients with spinal muscular atrophy (SMA) found in healthcare settings. The company has plans to add Qdata modules for other neurological diseases, such as Parkinson’s disease, Neuromyelitis Optica Spectrum Disorder (NMOSD), and more.

For more information about Qdata MS, visit:

About Verana Health

Verana Health® is a digital health company that increases quality in real-world data. Verana Health operates an exclusive real-world data network of more than 20,000 healthcare providers (HCPs) and approximately 90 million de-identified patients, resulting from its strategic data partnerships with the American Academy of Ophthalmology®, American Academy of Neurology, and American Urological Association. Using its clinician-informed and artificial intelligence-enhanced VeraQ™ population health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata™. Verana Health’s Qdata helps power analytics solutions and software-as-a-service products for real-world evidence generation, clinical trial activation, HCP quality reporting and medical registry data management. Verana Health’s quality data and insights help drive advances in medicine to improve the quality of care and quality of life for patients. For more information, visit

Media contact:
Megan Moriarty
Amendola Communications
[email protected]

SOURCE Verana Health


Related Posts